Use Case

Building on their initial hit series, Variational AI and Rakovina Therapeutics share promising new results on ATR inhibitors generated with Enki. The latest findings reveal compounds that balance potency, selectivity,… Read More about Update: Advancing CNS-penetrant ATR inhibitors with Enki™

Following their successful 2022 collaboration, which targeted the SARS-CoV-2 main protease, Variational AI and Life Chemicals have partnered for a second time to discover de novo generated selective dual EGFR/FGFR1… Read More about Variational AI & Life Chemicals join forces to discover selective dual EGFR/FGFR1 inhibitors using generative AI

Variational AI partnered with Rakovina Therapeutics to support the discovery of a brain-penetrant ATR inhibitor using our Enki™ generative AI platform. By generating and prioritizing novel, CNS-targeting compounds aligned with… Read More about Accelerating the Discovery of Brain-Penetrant ATR Inhibitors with Enki™